Trending...
- Levinger-Regens Analytics Reveals New Energy Outlook
- 'Back to the Future,' 'Stranger Things Q&As Headline Programming at FAN EXPO Philadelphia
- Next Sparc Growth Partners Launches Elevated Website
Eve Wellness located in SF offers the first FDA-approved ultrasound screening technology specifically designed for detecting cancer in dense breast tissue.
SAN FRANCISCO - PennZone -- Eve Wellness, a San Francisco-based breast cancer screening clinic, is leading the charge in breast cancer screening by providing women the opportunity to get screened earlier, at any age, without a doctor referral, using their FDA-Approved GE ABUS ultrasound technology, powered by FDA-Approved AI (artificial intelligence), all without radiation. This comes on the heels of the FDA's new mandate, announced on March 9, 2023, requiring all mammography facilities to report breast density information and enhance communications with patients and providers.
The FDA's move is important because the risk of breast cancer is of real concern to many patients, said Dr. Harold Burstein, a medical oncologist at the Dana-Farber Cancer Institute in Boston and a professor at Harvard Medical School. "The identification of dense breast tissue can be a marker of slightly greater risk of getting breast cancer, and it may need additional breast imaging," said Burstein, who likened the challenge of reading mammograms to "looking through frosted glass."
More on The PennZone
Breast density has been identified as a risk factor for breast cancer, and the FDA's new mandate aims to increase awareness and understanding of this risk. The mandate requires mammography facilities to provide patients with information about their breast density and the impact it can have on the accuracy of mammograms. Facilities are also required to communicate the findings with healthcare providers and provide recommendations for additional screening options, such as breast ultrasound.
"Today's action represents the agency's broader commitment to support innovation to prevent, detect and treat cancer," said Hilary Marston, M.D., M.P.H., FDA's Chief Medical Officer. "Since 1992, the FDA has worked to ensure patients have access to quality mammography. The impact of the Mammography Quality Standards Act on public health has been significant, including a steep decrease in the number of facilities that do not meet quality standards. This means that more women have access to consistent, quality mammography. We remain committed to advancing efforts to improve the health of women and strengthen the fight against breast cancer."
At Eve Wellness, breast ultrasound is the best option for women with dense breast tissue. Their GE ABUS ultrasound technology, powered by AI, can detect breast cancer at an earlier stage and without the use of radiation. With physician-read results back in less than 48 hours, Eve Wellness provides women with quick results, reducing anxiety and enabling early intervention.
More on The PennZone
"Breast cancer claims the lives of nearly 43,000 women annually, and early detection is key to improving outcomes. Eve is on a mission to fill the void in breast cancer screening," said Brendan Foley, Co-Founder at Eve Wellness. "We are proud to lead the change in breast screening by providing women with access to the latest technology and empowering them to take control of their breast health."
Eve Wellness is committed to providing women with the best possible breast cancer screening options and is a game-changer in the fight against breast cancer. With the FDA's new mandate, women can feel more informed and empowered in their breast health decisions, and Eve Wellness is here to support them every step of the way.
For more information on Eve Wellness and their breast cancer screening services, visit their website at https://www.myevewellness.com/.
The FDA's move is important because the risk of breast cancer is of real concern to many patients, said Dr. Harold Burstein, a medical oncologist at the Dana-Farber Cancer Institute in Boston and a professor at Harvard Medical School. "The identification of dense breast tissue can be a marker of slightly greater risk of getting breast cancer, and it may need additional breast imaging," said Burstein, who likened the challenge of reading mammograms to "looking through frosted glass."
More on The PennZone
- Australian Battery Recycling Technology Startup Advances Its Innovative Battery Metals Recovery Process
- Governor Shapiro Highlights Universal Free Breakfast Proposal for Pennsylvania Students in Visit to Montgomery County Elementary School
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of SentinelOne, Inc. (S) on Behalf of Investors
- ASR Media Productions to Own and Operate Local Magazine, Fig Lehigh Valley
- Trump Bus Tour sponsored by Legacy PAC will roll into the Georgia GOP State convention June 9th and 10th Columbus Georgia
Breast density has been identified as a risk factor for breast cancer, and the FDA's new mandate aims to increase awareness and understanding of this risk. The mandate requires mammography facilities to provide patients with information about their breast density and the impact it can have on the accuracy of mammograms. Facilities are also required to communicate the findings with healthcare providers and provide recommendations for additional screening options, such as breast ultrasound.
"Today's action represents the agency's broader commitment to support innovation to prevent, detect and treat cancer," said Hilary Marston, M.D., M.P.H., FDA's Chief Medical Officer. "Since 1992, the FDA has worked to ensure patients have access to quality mammography. The impact of the Mammography Quality Standards Act on public health has been significant, including a steep decrease in the number of facilities that do not meet quality standards. This means that more women have access to consistent, quality mammography. We remain committed to advancing efforts to improve the health of women and strengthen the fight against breast cancer."
At Eve Wellness, breast ultrasound is the best option for women with dense breast tissue. Their GE ABUS ultrasound technology, powered by AI, can detect breast cancer at an earlier stage and without the use of radiation. With physician-read results back in less than 48 hours, Eve Wellness provides women with quick results, reducing anxiety and enabling early intervention.
More on The PennZone
- NetDiligence Announces Recipients of 2023 Toby Merrill Awards
- Pettit Kohn Welcomes Esteemed Attorney John E. Drazkowski to the Arizona Team
- GTM Training Institute Expands Offerings with Income Tax Compliance-Specific Program for In-House Tax & Finance Professionals
- INshed Now Offers Nationwide Shipping of Fully-Assembled, Eco-Friendly Backyard Offices
- INVESTIGATION ALERT: Berger Montague is Investigating Securities Fraud Claims on Behalf of Investors in Funds Sponsored by Freedom Impact Consulting, LLC
"Breast cancer claims the lives of nearly 43,000 women annually, and early detection is key to improving outcomes. Eve is on a mission to fill the void in breast cancer screening," said Brendan Foley, Co-Founder at Eve Wellness. "We are proud to lead the change in breast screening by providing women with access to the latest technology and empowering them to take control of their breast health."
Eve Wellness is committed to providing women with the best possible breast cancer screening options and is a game-changer in the fight against breast cancer. With the FDA's new mandate, women can feel more informed and empowered in their breast health decisions, and Eve Wellness is here to support them every step of the way.
For more information on Eve Wellness and their breast cancer screening services, visit their website at https://www.myevewellness.com/.
Source: Eve Wellness, Inc.
Filed Under: Health
0 Comments
Latest on The PennZone
- Studeo dévoile StudAI : l'Intelligence Artificielle au service de l'éducation
- Pennsylvania Based Trauma & Crime Scene Remediation Firm in High Demand
- EMH Productions Announce 'Live for Liberty' Charity Concert in Los Angeles Supporting "Woman, Life, Freedom" Movement in Iran
- Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023
- Pennsylvania: Governor Shapiro Announces Plans to Expand Keystone Early Learning Center
- ICYMI: In a "Watershed Moment for What It Means to Live and Age in Pennsylvania," Governor Shapiro Directs Department of Aging to Develop a 10-Year Master Plan for Older Adults
- NEMTAC® Brings Innovation to Accreditation Industry with the Launch of Collaborative Network Built on Distributed Ledger Technology
- Latino Leaders Network to Honor Mayor Kate Gallego of Phoenix with the Antonio Villaraigosa Leadership Award at the 38th Tribute to Mayors
- The Facial Surgery Center Now Uses Guided Implant Surgery For Accurate Dental Implant Placements!
- Century Fasteners Corp. – Robert D. Botticelli, Hired
- Levinger-Regens Analytics Reveals New Energy Outlook
- 'Back to the Future,' 'Stranger Things Q&As Headline Programming at FAN EXPO Philadelphia
- Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference
- UVify Unveils the Groundbreaking SLAMDAQ
- Plug Power Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Plug Power Inc. of Deadline in Securities Fraud Class Action Lawsuit
- Dancing Numbers Unveils Google Sheets QuickBooks Integration, Streamlining Data Import, Export, and Deletion
- Currier Repeats as Transition Player of the Year, Del Bianco and Harris Take Home First Awards
- Securities Class Action Reminder (NASDAQ: IEP): Kessler Topaz Meltzer & Check, LLP Reminds Icahn Enterprises L.P. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit
- FRG Investigation Notification: Kessler Topaz Meltzer & Check, LLP is Investigating Claims on Behalf of Franchise Group, Inc. (NASDAQ: FRG) Current Shareholders
- ReadyCommunities Partnership of CCROA Announces National Service Awardees Who Helped Save Passengers from the Derailed Train Near Rural Mendon